Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Business Forum Partnering
Doing it right
Deal phases
Source: Thomson Reuters Cortellis
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
50.0%
% of develop...
Preclinical deals
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
% of pre-clinical development/commercialization deals by t...
Phase 1 deals
Source: Thomson Reuters Cortellis
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
% of phase 1 development/commercializati...
Phase 2 deals
Source: Thomson Reuters Cortellis
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
20.0%
% of phase 2 ...
Phase 3 deals
Source: Thomson Reuters Cortellis
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
% of phase 3 development/commercia...
#BIO2014
convention.bio.org
Upcoming SlideShare
Loading in …5
×

Therapeutic Trends in Deals – BIOs top 10

829 views

Published on

This powerpoint gives you insights into the percentage of development/commercialization deals by highest phase at deal start (May 2012 - May 2014)

Published in: Business
  • Login to see the comments

  • Be the first to like this

Therapeutic Trends in Deals – BIOs top 10

  1. 1. Business Forum Partnering Doing it right
  2. 2. Deal phases Source: Thomson Reuters Cortellis 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0% % of development/commercialization deals by highest phase at deal start May 2012 - May 2014
  3. 3. Preclinical deals 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% % of pre-clinical development/commercialization deals by therapeutic area May 2012 - May 2014 Source: Thomson Reuters Cortellis
  4. 4. Phase 1 deals Source: Thomson Reuters Cortellis 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% % of phase 1 development/commercialization deals by therapeutic area May 2012 - May 2014
  5. 5. Phase 2 deals Source: Thomson Reuters Cortellis 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 18.0% 20.0% % of phase 2 development/commercialization deals by therapeutic area May 2012 - May 2014
  6. 6. Phase 3 deals Source: Thomson Reuters Cortellis 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% % of phase 3 development/commercialization deals by therapeutic area May 2012 - May 2014
  7. 7. #BIO2014 convention.bio.org

×